LEXINGTON, Mass.--(BUSINESS WIRE)--May 27, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the
Company will present at the Jefferies 2015 Global Healthcare Conference
on Wednesday, June 3, at 11:30 a.m. (ET) in New York.
A live webcast
and replay of the presentation will be available on the "Investors"
section of the Company's website, www.syntapharma.com.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical
company focused on research, development and commercialization of novel
oncology medicines that have the potential to change the lives of cancer
patients. Synta’s lead oncology drug candidate, ganetespib, a novel heat
shock protein 90 (Hsp90) inhibitor, is currently being evaluated in
several clinical trials including the pivotal GALAXY-2 Phase 3 trial in
non-small cell lung cancer. Building on its extensive expertise in the
science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor
Drug Conjugate (HDC) small molecule drug development program. IND
enabling studies have commenced for the first clinical candidate from
the HDC program, STA-12-8666, and preclinical evaluation of additional
HDC candidates is ongoing. For more information, please visit www.syntapharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150527006523/en/
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Andrea Rabney, 212-600-1494
Eliza Schleifstein, 917-763-8106